Skip to main content
. 2021 Nov 14;27(42):7340–7349. doi: 10.3748/wjg.v27.i42.7340

Figure 1.

Figure 1

Alpha diversity indices (Shannon index) of hepatocellular carcinoma patients based on treatment and prognosis. A: The Shannon index of the non-responders on admission (T0) was not significantly lower than that of the responders (P = 0.14); B: The Shannon index of the non-responders was significantly lower than that of the responders after nivolumab therapy (T1); C: Nivolumab therapy did not alter the Shannon index. HCC: Hepatocellular carcinoma.